DeepScribe AI Medical Scribe: Workflow, Privacy, Pricing, and Evidence (2026)

DeepScribe is an AI medical scribe that turns clinical conversations into draft documentation and connects that work with EHR workflows. If you searched for “deep scribe,” this guide concerns the healthcare vendor at deepscribe.ai, not similarly named meeting-transcription tools. Its current positioning emphasizes specialty care and oncology, with documentation, pre-chart preparation and coding capabilities. DeepScribe product overview.

Our buying assessment: DeepScribe belongs on the shortlist when an embedded EHR workflow is a core requirement, especially for an oncology practice using a documented integration. Do not buy on an assumed monthly price or a diagnosis-capture statistic. Obtain a scoped quote, verify your actual EHR destination and measure the work needed to turn a draft into a signed record.

Publisher disclosure: Vero sells competing AI scribe software. This public-evidence assessment is by Lauren Bennett, not an independent clinician’s hands-on review. Sources checked September 21, 2026. No live DeepScribe session or product screenshot capture was performed, and separate clinician or health-IT review has not been completed. The scripts below are proposed tests, not product results. See our editorial policy.

DeepScribe cost and quote requirements

We did not find a verified public list price in the official pages checked September 21, 2026. DeepScribe’s purchasing route is a demo and sales conversation. A third-party “Deep Scribe price” estimate is not a current vendor quote. This assessment also did not verify a standard free-plan or trial entitlement.

Ask for a quote that names the product bundle, practice size, deployment route and contract period. A per-clinician price is not comparable with an organization-wide fee until you know minimum seats, activation dates and interface costs. Distinguish a sales demonstration from an evaluation environment your team can use and from a production pilot with contractual obligations.

On a narrow screen, scroll tables horizontally. Each table region can also receive keyboard focus.

Compare total cost with the same units

Use this planning formula: first-year cost = recurring fees × billed months + setup and interface fees + implementation labor + ongoing review, transfer and recovery labor. Add only costs that belong to the workflow; avoid counting the same clinician minutes twice.

For an illustrative clinic completing 180 encounters each month, a two-minute difference in review and transfer time represents six hours monthly. At a clinic-assigned value of $120 per hour, that is $720 of time value. These are invented planning inputs, not a DeepScribe price, measured saving or promise of additional revenue. Time only becomes recoverable capacity when scheduling and staffing allow it.

Record both the median and slowest sessions in a pilot. A short average review time can conceal occasional drafts requiring extensive reconstruction. Include capture failures and unsuccessful EHR transfers in the denominator rather than reporting only completed notes. Our digital scribe pilot guide covers the broader baseline-versus-assisted comparison; this page focuses on the purchasing and destination questions specific to evaluating DeepScribe.

Workflow and EHR integration

DeepScribe’s medical scribe page, checked September 21, describes selecting a patient from a synchronized schedule, capturing the encounter and receiving structured documentation for clinician review. It also describes customization, pre-chart preparation and coding functions. These are documented capabilities, not behavior we observed in a product session.

The same page advertises telemedicine support and conversations in more than 110 languages. Neither statement establishes compatibility with every conferencing setup or equivalent accuracy across languages. Confirm the current operating-system, microphone and account requirements; this assessment does not verify a complete mobile-device support matrix.

The workflow to demonstrate

1. 1. Match the encounter

   Correct patient, visit and historical context.

2. 2. Capture the conversation

   Expected speakers, permitted boundaries and visible capture state.

3. 3. Review the draft

   Source attribution, corrections, diagnoses and missing information.

4. 4. Inspect the saved record

   Correct fields, one intended note and the appropriate signature state.

Vero’s evaluation map—not a DeepScribe interface screenshot.

How DeepScribe’s core features work

These mechanisms come from official product documentation checked September 21, 2026. We have not observed their behavior in a live account; confirm the included modules and controls for your deployment.

Customization Studio: edits become proposed rules

DeepScribe describes this sequence: review a note, edit it, select “Learn,” then accept proposed customizations for future notes. Rules can be refined in plain language. It also describes using past notes and visit-specific preferences. Customization Studio.

The potential value is reducing repeated formatting edits. In a demo, change a heading, inspect the proposed rule and generate another synthetic note. Check that a one-patient factual correction does not become a general instruction. Rule scope, rollback and behavior across clinicians remain unverified here.

SmartPrep: different preparation for consults and follow-ups

SmartPrep describes assembling EHR information into a pre-visit summary: clinical history for an initial consultation, versus interval events for a follow-up. Its checklist surfaces outstanding orders, follow-ups and results; pre-visit information can carry into the current note. DeepScribe describes access through supported EHR workflows and its desktop/mobile apps.

That could reduce chart searching, but a summary is only as useful as its source coverage and chronology. Ask the demonstrator to identify the source and date of a finding, then show what happens when a newer document contradicts it. Verify which outside records are actually available, how recent updates arrive, and whether a pending result stays pending after note generation. We have not tested retrieval completeness, update delays or the handling of conflicting records. The oncology example below illustrates these boundaries without simulating a SmartPrep screen.

AI coding: three different tasks, not one accuracy claim

DeepScribe’s AI coding page describes E/M recommendations informed by the conversation, visit length and complexity; HCC-oriented condition capture; and ICD-10 suggestions combining historical EHR information with current conversation. These are vendor descriptions, not a verified reimbursement or coding-accuracy result.

Evaluate each separately: ask for the evidence behind an E/M suggestion, the provenance and current status of a carried-forward condition, and the documented basis for a diagnosis code. Confirm whether a suggestion remains a proposal or is written to a destination field, and who accepts it. A recorded conversation’s duration should not be assumed to establish billable time. Final selection requires qualified human review of the applicable rules and record. We have not validated the suggested codes, audit trail or claim outcomes; more suggested codes do not by themselves establish better coding.

Three documented EHR routes

The following describes official integration pages checked September 21, 2026. Availability in a particular tenant, edition or contract still needs confirmation. The acceptance questions are our editorial evaluation criteria, not claims that these defects occur in DeepScribe.

Do not accept “integrated” as a single pass/fail label. Reading a schedule, importing history, writing a narrative note and suggesting a diagnosis are different permissions and transactions. A demo can succeed at one and omit another. Ask the demonstrator to finish the encounter in the actual destination, not stop at the generated draft.

For deployment, name a clinical owner for note content and an interface owner for mappings and recovery. Keep an accepted example of each required note type, including an empty optional field. Recheck after a template, model or EHR change. The EHR integration guide provides architecture and implementation criteria without treating every connected product as interchangeable.

Privacy, security and exit terms

Start with the agreement and the data flow, not a badge. HHS cloud guidance explains the role of business associate agreements, risk analysis and safeguards. A vendor’s HIPAA statement does not approve your particular recording process or replace organizational review.

DeepScribe’s public terms, checked September 21, address service operation and improvement, usage information and de-identified data. The business associate provisions permit de-identification under the HIPAA standard, and the terms allow certain uses of de-identified information beyond the subscription. Do not treat identifiable clinical data, usage data and de-identified data as one contractual category. Have the privacy lead reconcile these provisions with the signed agreement.

The privacy policy discusses U.S. processing locations, purpose- and obligation-dependent retention, and practice responsibilities. It does not establish one simple deletion countdown for every clinical deployment. Ask for the applicable schedule rather than assuming recordings, transcripts, notes and backups disappear together.

The security-practices page describes encryption, access controls, audits and incident-response arrangements. Those are vendor statements. Request current assurance evidence and its covered systems through the trust center; this assessment does not independently certify those controls.

Renewal, termination and export

Section 6 of DeepScribe’s public terms describes renewal for a matching term unless the order form specifies otherwise, with at least 30 days’ written nonrenewal notice. Service access ends on termination. Confirm the controlling order form, notice method and final access date before committing. Terms checked September 21, 2026.

Request a written export procedure while access remains active: which records are available, format, delivery time, fees and verification method. Do not assume a post-termination grace period. Test whether the export preserves authorship, timestamps and the information your records policy requires; retain clinical records in the approved system, not solely in a subscription workspace.

DeepScribe’s acceptable use policy identifies negotiated agreement precedence and restricts automated extraction. Obtain appropriate permission for competitor-led testing, recordings and publication of screenshots or outputs. The test cases below are not authorization to bypass account or contractual restrictions.

For a Canadian practice, establish the relevant provincial health-information and federal or provincial private-sector requirements before considering a deployment. The Office of the Privacy Commissioner’s jurisdiction overview explains why a U.S. compliance statement is not a province-specific approval. This guide has not verified Canadian availability or a province-specific DeepScribe contract.

What the oncology evidence shows

An August 2025 Journal of Clinical Pathways abstract by Campetti and colleagues describes DeepScribe/OncoEMR use across 17 practices, 258 sites, 215 physicians and 405,210 encounters. Diagnosis analysis covered four practices and 71 providers. Affiliations include Flatiron Health and DeepScribe.

Reported 72-hour note closure was 84.2% for AI encounters versus 83.5% for non-AI encounters; diagnoses per visit increased 16% in the subset. However, accuracy was not explicitly evaluated. More diagnoses do not establish more correct coding or improved outcomes.

This observational/pre-post implementation abstract is not an independent randomized comparison. It provides oncology deployment evidence, not proof of causality or equivalent effects in another specialty, EHR or configuration.

For your own evaluation, keep three outcomes separate: documentation completeness, clinical correctness and operational effort. A more detailed note can still contain an attribution error; a rapidly completed note can still require lengthy correction. Require source-grounded review before interpreting longer notes or more diagnoses as a benefit.

Interpreting the vendor’s headline metrics

The Customization Studio page, checked September 21, displays 99.92% note approval and 1.6 minutes average chart closure. These are vendor claims, not validated benchmarks in this assessment. The headline presentation does not establish the denominator, sampling period or timing boundaries.

Ask whether approval follows corrections, who approves, and whether failed sessions are excluded. Ask when closure timing starts and whether it includes review, transfer and recovery. Neither figure establishes clinical accuracy. Do not combine them with the oncology abstract as though they share one cohort or methodology.

Six synthetic cases for an authorized evaluation

Proposed protocol, not executed: no authorized product session is available for this assessment. These fictional cases specify expected documentation boundaries—not observed performance. Use an approved sandbox with clinical and interface reviewers. Do not simulate failures in production.

Record date, available version, configuration, EHR edition, template, language, device, microphone and capture route. Keep the raw draft, corrections and saved sandbox record; measure editing and transfer time separately. Missing product evidence cannot be replaced by a mock screenshot.

Run six cases twice: 12 planned sessions, first quiet, then with a fixed non-speech background track. Record the track, playback level and distance. Keep speakers, speaker positions, microphone placement and speaking pace fixed; only the background-noise condition changes. This small rehearsal cannot estimate population-level accuracy.

D-01: oncology history, current status and pending findings

Fictional editorial example; not clinically reviewed and not an observed DeepScribe output. This illustrates attribution and chronology, not treatment or coding advice.

Supply this test context: “Historical oncology summary: adjuvant treatment completed May 2025. Imaging performed September 18, 2026; report pending.” Read: Clinician: “Today is September 21. The previous treatment is completed; we have not documented a new treatment decision today.” Patient: “I feel less tired than at the last visit.” Clinician: “The imaging report is still pending. The designated clinician will review it when available.”

Keep these three parts separate in the expected teaching note:

• History: the supplied record states treatment completed in May 2025; it is not a current treatment order.
• Current visit: the patient reports less fatigue. No new treatment decision is documented; this does not establish disease response.
• Pending information: the September 18 imaging report remains unavailable, with review assigned to the designated clinician when it arrives.

Do not invent stage, recurrence, remission, imaging findings or a medication plan. Inspect both the pre-chart summary and current note for a pending finding becoming a confirmed conclusion. Clinical approval of this example remains outstanding.

D-02: assign statements to the right speaker

Read: Patient: “I have not been dizzy.” Companion: “I was dizzy this morning, not the patient.” The patient must not acquire the companion’s symptom.

Keep speaker positions unchanged in the two base sessions. An optional distance challenge must keep the script, background-noise condition and other setup unchanged; record the distance and report it separately from the 12-session quiet/noise protocol.

D-03: preserve diagnostic uncertainty

Read: Clinician: “Infection is a possibility, not a diagnosis today. The next step is review of the pending result.” Check that the narrative and suggested diagnosis fields preserve uncertainty, without invented treatment or dates.

D-04: retain the corrected number

Read: Patient: “It started twelve days ago—sorry, two days ago, not twelve.” Clinician: “Two days ago is correct.” Both the draft and saved note must retain two, without contradictory durations elsewhere.

D-05: recognize a missing audio channel

In the intended telehealth setup, transmit “My concern is fatigue,” then mute the remote test speaker’s channel before “It improved yesterday.” Restore audio: “Part of the audio was missing; please repeat the update.” Inspect the raw draft before repetition: it must not invent the missing improvement. Confirm both audio channels with the actual headset.

D-06: verify handoff and controlled recovery

Read: “Test encounter D-06: documentation demonstration only; no examination or treatment performed.” Review and transfer to the sandbox. Check encounter, sections, signature state and duplicates. If an approved failure mechanism exists, the interface owner can simulate a failed transfer and one retry; record the failure signal and reconciliation result.

No draft, correction-time result or completed EHR transfer from these cases is available. A future authorized demonstration should show all three—not just a successful draft. For broader capture testing, use the ambient scribe guide.

Who should shortlist DeepScribe?

These are buyer-fit inferences from the sources above, not product rankings. The strongest documented reason to evaluate DeepScribe is the connection between capture, preparation and EHR review. The main purchasing limitations in this assessment are unverified public pricing, configuration-dependent availability and a lack of our own measured product results.

Where Vero fits in the comparison

Vero’s note-creation documentation, checked September 21, describes starting from recordings, typed context, uploaded documents, images or audio, then selecting a template and reviewing the draft. Its documented handoff includes copying and available export options. That mixed-input workflow is worth comparing when the source material is not only an ambient encounter.

DeepScribe’s documented embedded routes deserve a separate integration test; copying a note is not the same as a bidirectional interface. Conversely, an EHR connection does not by itself establish better source handling. Use the same expected facts, review criteria and final-record checks for both products. This article does not establish that Vero is more accurate, cheaper for your deployment or clinically superior.

Before deciding, require three things together: an acceptable contract and quote, a demonstrated destination workflow, and reviewed evidence from your representative cases. If any remains unresolved, name the owner and the proof needed. A polished demo is a useful start—not the completed procurement decision.